PacBio’s $600M Omniome buyout brings together long & short of DNA sequencing

PacBio’s $600M Omniome buyout brings together long & short of DNA sequencing

Source: 
MedCity News
snippet: 

DNA sequencing company Pacific Biosciences has reached a $600 million agreement to acquire Omniome, a startup with complementary sequencing technology. The cash and stock deal comes about 18 months after antitrust concerns led PacBio and sequencing giant Illumina to terminate their tie-up.